Therefore, especially for CLL patients with active NOTCH1 signaling, AZ1 or other USP28 inhibitors such as CT1113 recently tested in T-ALL [82] might be optimal partners for rational therapeutic combinations with venetoclax. This evidence concerns the gene USP28 and B-cell chronic lymphocytic leukemia.